Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Study Shows Wegovy Can Help Heart Failure Patients Decrease Medication Use

Reading Time: < 1 minute

A groundbreaking study presented at the Heart Failure 2024 meeting in Lisbon, Portugal, has revealed that the weight loss drug Wegovy (semaglutide) may hold the key to reducing the need for loop diuretics in patients with heart failure.

Dr. Kavita Sharma, the lead author of the study and an associate professor of medicine at Johns Hopkins University School of Medicine, shared that after a year of taking Wegovy, patients showed a significant reduction in average loop diuretic dose. This reduction was accompanied by a lower likelihood of diuretic treatment escalation and a greater likelihood of diuretic treatment de-escalation compared to those on a placebo.

The study focused on patients with heart failure with preserved ejection fraction (HFePF), a common form of the disease where the heart pumps normally but is too stiff to fill properly. The international trial included 1,145 obese patients with an average age of 70, half of whom were men and half were women.

Participants received either a placebo injection or a Wegovy shot once a week for 52 weeks. Those on Wegovy experienced significant weight loss and improvements in heart failure measurements, such as performance on a six-minute walking test.

Most notably, patients on Wegovy saw a 17% average decline in the need for loop diuretics, while those on the placebo experienced a 2.4% increase in diuretic use. The study also found fewer serious adverse events with Wegovy compared to the placebo.

These findings suggest that Wegovy may have disease-modifying effects that lead to better long-term clinical outcomes for patients with heart failure. However, as the study was presented at a medical meeting, it should be considered preliminary until published in a peer-reviewed journal.

Taylor Swifts New Album Release Health issues from using ACs Boston Marathon 2024 15 Practical Ways To Save Money